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The interleukin (IL)-1 family member IL-33 has been described as intracellular alarmin 
with broad roles in wound healing, skin inflammation but also autoimmunity. Its dichot-
omy between full length (fl) IL-33 and the mature (m) form of IL-33 and its release by 
necrosis is still not fully understood. Here, we compare functional consequences of 
both forms in the skin in  vivo, and therefore generated two lines of transgenic mice 
which selectively overexpress mmIL-33 and flmIL-33 in basal keratinocytes. Transgene 
mRNA was expressed at high level in skin of both lines but not in organs due to the 
specific K14 promoter. We could demonstrate that transgenic overexpression of 
mmIL-33 in murine keratinocytes leads to a spontaneous skin inflammation as opposed 
to flmIL-33. K14-mmIL-33 mice synthesize and secrete high amounts of mmIL-33 along 
with massive cutaneous manifestations, like increased epidermis and dermis thickness, 
infiltration of mast cells in the epidermis and dermis layers and marked hyperkeratosis. 
Using skin inflammation models such as IL-23 administration, imiquimod treatment, or 
mechanical irritation did not lead to exacerbated inflammation in the K14-flmIL-33 strain. 
As radiation induces a strong dermatitis due to apoptosis and necrosis, we determined 
the effect of fractionated radiation (12 Gy, 4 times). In comparison to wild-type mice, 
an increase in ear thickness in flmIL-33 transgenic mice was observed 25 days after 
irradiation. Macroscopic examination showed more severe skin symptoms in irradiated 
ears compared to controls. In summary, secreted mmIL-33 itself has a potent capacity in 
skin inflammation whereas fl IL-33 is limited due to its intracellular retention. During tissue 
damage, fl IL-33 exacerbated radiation-induced skin reaction.
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inTrODUcTiOn
The cytokine interleukin 33 (IL-33) is a member of the IL-1 family contributing to pathogenesis 
in allergic lung diseases (1, 2), atopic dermatitis (3), sepsis (4), inflammatory tendinopathy (5) but 
also to rheumatoid arthritis (6) and psoriasis (7). IL-33 is constitutively expressed in epithelial cells 
from tissues with a barrier function, as well as in endothelial cells and fibroblasts (8). Upon various 
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types of endothelial or epithelial cell damage, IL-33 is released 
and binds to the heterodimeric receptor complex ST2L/IL1-
RacP expressed on Th2 and diverse types of innate immune cells 
(9–11). IL-33 functions via two ways: firstly, IL-33 is a nuclear 
cytokine with restricted nuclear localization (12). In the nucleus, 
due to a helix turn helix like motif, IL-33 condenses chromatin 
(13) and has been suggested to suppress pro-inflammatory gene 
transcription (14). Secondly, as alarmin, released during cell 
damage, IL-33 activates the immune system (12, 15). Apoptosis 
deactivates IL-33 whereas necrosis provides IL-33 as a bioactive 
protein. During apoptosis, IL-33 will be cleaved by activated 
caspase 3 and 7 in the IL-1-like cytokine domain. This short form 
of IL-33 has an attenuated biological activity and no capacity 
to activate the immune system (16). Upon necrotic cell death 
or mechanical injury, the full length form of IL-33 (fl IL-33) 
is released in the extracellular space (15, 16). The inflamma-
tory proteases (neutrophil serine proteases, cathepsin G, and 
elastase) play an important role in the maturation process of fl 
IL-33 leading to a shorter mature form with increased biological 
activity (17). Interestingly, active externalization of IL-33 has 
been described by stimulation with proinflammatory cytokines 
such as tumor necrosis factor-alpha (TNF-α) (18).
So far, effector function of IL-33 is still under discussion, and 
multiple models of diseases have been described to be influenced 
by IL-33 signaling. In this notion, stimulation with IL-33 has 
been demonstrated to activate T-helper (Th)1, Th17, or Th2 
immune response (19). In models of lung inflammation, IL-33 
induced Th2 cytokines such as IL-5 and IL-13, as well as elevated 
levels of IL-1, IL-4, IL-6, IL-10 (20, 21). A mouse model with 
local overexpression of IL-33 in keratinocytes led to Th2 induced 
dermatitis (3). In contrary, under defined conditions, IL-33 can 
induce a Th1 immune response thereby producing Th1-type 
cytokines by natural killer and NKT cells (19, 22). Moreover, in 
Th1- and Th17-driven models of arthritis or psoriasis, IL-33 plays 
a proinflammatory role (7, 13, 21, 23).
In humans, IL-33 has been implicated in allergic inflammation 
such as asthma (24, 25) and atopic dermatitis (3, 26). In psoriatic 
skin increased IL-33 expression was detected on transcriptional 
(mRNA) and protein level but not in atopic dermatitis lesions 
or normal human skin (7, 18). Additionally, anti-TNF-α therapy 
downregulated IL-33 mRNA expression in skin of psoriatic 
patients (18).
Here, we wanted to elucidate the role of IL-33 in skin inflamma-
tion using different IL-33 expression models. Our work revealed 
a high skin inflammatory potential of IL-33 with an “alarmin” 
function during radiation.
MaTerials anD MeThODs
Mice
C57Bl/6 wild-type (WT) mice were obtained from Charles River 
Laboratories Sulzfeld, Germany. hK14mIL33tg were generated on 
a C57Bl/6 background (see below). KRT14-cre (CD1 background) 
mice were obtained from Jackson Laboratory (Bar Harbor, ME, 
USA). The mmIL-33-GFP-CRE mice (C57Bl/6 background) were 
kindly provided by Dr. S. Wirtz (27).
construction of the K14-il-33 Transgene
The transgene is expressed in a K14 expression vector (28). 
It consists of a 2-kb human keratin 14 promoter (Gen-Bank 
accession no. DQ343282.1), a 0.66-kb rabbit-beta globin intron 
followed by a 0.8-kb full-coding sequence of mouse IL-33 cDNA 
(Gen-Bank accession no. NM_133775.2) and a 0.35 kb human 
keratin 14 poly(A) signal DNA fragment. For generation of the 
vector encoding a secreted version of IL-33 (mmIL-33) controlled 
by skin-specific regulatory elements, we inserted mouse mature 
IL-33 cDNA into the K14 vector (27).
Transient Transfection
The human keratinocyte cell line HaCaT (#300493, CLS Cell 
Lines Service, Germany) and the murine keratinocyte cell line 
PDV were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% heat-inactivated fetal bovine serum 
(Invitrogen, Carlsbad, CA, USA), 100  U/ml penicillin and 
100  mg/ml streptomycin. Cells were maintained at 37°C and 
5% CO2. The K14 expression vector was transiently transfected 
into HaCaT cells using Lipofectamine 2000 transfection reagent 
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Murine keratinocytes were transfected using 
FuGENE® HD Transfection Reagent according to the manufac-
turer’s instruction (Promega, Madison, WI, USA).
Western Blot
After collecting the supernatant, all cells were pelleted, washed 
with cold phosphate-buffered saline (PBS), and lysed in RIPA 
buffer. Before denaturation with Laemmli buffer, protein con-
centration adjustment was conducted. Supernatants were resus-
pended in 6× Laemmli and boiled at 98°C for 10 min. Cell pellets 
and supernatants were separated on a 10% SDS-polyacrylamide 
gel. Membranes were blocked with 5% non-fat dry milk (Roth, 
Karlsruhe, Germany), probed with mouse anti-human IL-33 
antibody (1:1,000; Nessy-1, Enzo Life Sciences, Lörrach, 
Germany), and peroxidase-labeled anti-mouse as secondary 
antibody (Dako, Denmark). Membranes were developed using 
the enhanced chemiluminescence method.
Purification of Plasmid for Pronuclear 
injection
Linear transgene K14-IL-33 DNA fragment was separated from 
vector backbone by gel electrophoresis. The K14-IL-33 fragment 
was cut out, transferred in a dialysis bag (Spectra/Por MWCO 
3500, Spectrumlabs, DG Breda, The Netherlands), filled with 
running buffer (1× TAE), and closed with clamps. After electro-
phoresis for 1 h at 80 V, 90% of the DNA was eluted. The DNA 
was purified by Elutip-D minicolumns from Schleicher & Schuell 
(Dassel, Germany).
generation of Transgenic Mouse lines
The generation of transgenic mice by pronuclear injection 
of K14-IL-33 transgene was performed by the Transgenic 
Mouse Facility, Friedrich-Alexander-Universität Erlangen-
Nürnberg, Germany. Of 16 pups born, 2 mice were positive 
for the transgene. The transgenic founders were identified 
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by PCR for expression of the K14 promoter (IL-33-seq7fw 
5′ CAGTTGATCCCAGGAAGAGC 3′ and IL-33-seq6rev 
GCAGGCTACACTTTCCCATC) and K14-IL-33 transgene 
(IL-33-seq7fw CAGTTGATCCCAGGAAGAGC and IL-33-
seq2rev GTTGCAGCTCTCATCTTTCTCC) and by quantitative 
real-time PCR for the expression of mouse IL-33 using the primer 
pair: K14IL-33int/ex fw CTGCAAGTCAATCAGGCGAC and 
K14IL-33 int/ex rv TGCAGCCAGATGTCTGTGTC. A mouse 
line that highly overexpressed IL-33 was generated from these 
mice by breeding with littermates. To establish K14-CreERTM/
GFPmmIL33 mice, homozygous K14-CRETM mice were crossed 
with heterozygous tamoxifen inducible mmIL-33-GFP-CRE 
mouse. The offspring were tested for mmIL-33 expression 
using flow cytometric analysis of blood for GFP expression 
(Figure  3B) thus using negative littermate animals as control 
mice for all experiments.
All protocols used in these studies were in compliance with 
federal guidelines and the Amgen Institutional Animal Care and 
Use Committee. All mice were maintained in a SPF facility. All 
animal experiments were approved by the animal welfare com-
mittee and approved by the “Regierung Unter-/Mittelfranken.”
In Vivo imiquimod (iMQ) Treatment
The right ears of both WT and hK14mIL33tg mice at 8–10 weeks 
of age were topically treated with an IMQ-containing cream 
(Aldara, MEDA Pharma) for 7 consecutive days. Control ears 
were treated similarly with a vehicle cream. Ear swelling was 
measured daily before treatment. On day 7, after sacrificing the 
mice, ears were collected for H&E, immunohistochemistry (IHC) 
and analyzed for epidermal thickness.
acute Barrier Disruption Procedures
Barrier disruption due to removement of corneocytes was 
induced by skin stripping as reported previously (29). On day 
3 after treatment, back skin of WT and hK14mIL33tg (Tg) were 
collected for immunohistochemical staining for IL-33, H&E and 
analyzed for epidermal thickness (mm).
il-23-Dependent skin inflammation Model
500 ng IL-23 (R&D Systems, Minneapolis, MN, USA) in a total 
volume of 20 µL was intradermally injected in the ears from WT 
and hK14mIL33tg (Tg) every other day. Sterile PBS was used as 
a vehicle control. Ear thickness was monitored before each injec-
tion. On day 15, ears were analyzed for epidermal thickness and 
collected for immunostaining.
In Vivo radiation
Dermatitis was induced by locally and fractionated irradiation 
of the right ear similar to a procedure used for mouse tumor 
irradiation with slight modifications (30). For irradiation, mice 
were anesthetized by isoflurane inhalation and placed in a special 
manufactured plexiglas® box. During the irradiation procedure, 
the mice were kept under isoflurane inhalation anesthesia to 
avoid movement of the mice. The mice were locally irradiated 
with four single fractions of 12 Gy (cumulative dose of 48 Gy) 
only at the right ear. The irradiation field of the 6 MV linear accel-
erator (PRIMART, Siemens, Munich, Germany) was minimized, 
and irradiation was performed tangentially to preserve the head 
of the mice. This procedure was performed at days 1, 3, 5, and 7. 
Starting on day 2 and every second day thereafter, animals were 
scored in a blinded manner for ear thickness and dermatitis. 
Dermatitis scoring of all animals was performed analog to the 
Cancer Therapy Evaluation Program scale (31, 32). Briefly, der-
matitis scoring ranged from: 0 = normal, no changes; 1 = mild 
erythema; 2 = moderate to severe erythema, slight desquamation; 
3 = desquamation of 25–50% of irradiated area; 4 = desquama-
tion of >50% of irradiated area; to 5 = frank ulcer.
In Vitro irradiation
K14 fl IL-33 transfected murine keratinocytes (PDV) were incu-
bated at 37°C, 5% CO2 in humidified air in 24 well, flat-bottom 
plates. Ionizing irradiation was performed with an X-ray genera-
tor (120 kV; GE Inspection Technologies, Hürth, Germany). The 
dose rate was 8  Gy/min. Irradiated and control keratinocytes 
monolayer cultures were immediately returned to the incubator 
at 37°C in a humidified environment and cultured for 6–48  h. 
Supernatant and cells were analyzed by ELISA and western blot 
to assess the presence of the IL-33 cytokine.
Tamoxifen Preparation and administration
Tamoxifen (Cayman Chemical, Ann Harbor, MI, USA) was 
dissolved in an ethanol/DMSO mixture (equal parts) solutions 
at 100 mg/ml. Tamoxifen solution was freshly prepared the day 
prior to each administration and placed on a rolling device to dis-
solve overnight at room temperature. Before treatment, excess fur 
was shaved from the backs of recipient mice, which were topically 
treated with 20 mg Tamoxifen (200 µl volume).
histology and ihc
Mouse skin and ear samples were fixed in 4% formaldehyde 
and stained with hematoxylin and eosin. Epithelial hyperplasia 
was assessed using a Zeiss Axio Lab.A1 light microscope (Zeiss, 
Oberkochen, Germany) and quantified by measuring the mean 
distance from the stratum basale to the bottom of the stratum 
corneum in a blinded manner. Mast cells were stained by toluidine 
blue, numbers counted per full skin section and standardizing for 
the tissue area of different sections [using image analysis system 
(OsteoMeasure; OsteoMetrics, Decatur, GA, USA)].
For IHC, 8-µm paraffin sections were incubated with anti-
mouse IL-33 antibody (Enzo Life Sciences, Lörrach) overnight 
at 4°C. Tissues were subsequently labeled with biotinylated goat 
anti-mouse IgG antibody (Vector Laboratories, Burlingame, CA, 
USA) at room temperature for 1 h, following streptavidin-HRP 
(Dako, Denmark) and DAB Chromogen (Dako, Denmark) incu-
bation. Positive staining developed as a brown reaction.
Quantitative real-time Pcr analysis
Total RNA was isolated using peqGold TriFast from Peqlab 
(Erlangen, Germany). RNA was reverse transcribed using the 
MultiScribe™MuLV reverse transcriptase (Invitrogen, Thermo 
Fisher Scientific Inc., Waltham, MA, USA). Relative gene expres-
sion was measured with Sybr Green RT mix by quantitative 
real-time PCR using β-actin as endogenous control accord-
ing to the manufacturer’s manual (Applied Biosystems 7500 
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fast-real-time-PCR System or Quant StudioTM 6 Flex Real-Time 
PCR systems). For evaluation of target gene expression, the ΔCt 
as well as the ΔΔCt method was used (all Applied Biosystems, 
Carlsbad, CA, USA).
The following primers were used: mIL-33 (fw 5′CTGCA 
AGTCAATCAGGCGAC 3′, rv 5′ TGCAGCCAGATGTCTGT 
GTC 3′) β-Actin (fw 5′ TGTCCACCTTCCAGCAGATGT 3′, 
rv 5′ AGCTCAGTAACAGTCCGCCTAGA 3′) mIL-1β (fw 5′ CAG 
GCAGGCAGTATCACTCA 3′, rv 5′ AGGTGCTCATGTCCTC 
ATCC 3′) mIL-6 (fw 5′ TCCATCCAGTTGCCTTCTTG 3′, rv 
5′ TTCCACGATTTCCCAGAGAAC 3′) mIL-19 (fw 5′ GCCA 
ACTCTTTCCTCTGCGT 3′, rv 5′ GGTGGCTTCCTGACTGC 
AGT 3′) mIL-5 (fw 5′ AGCACAGTGGTGAAAGAGACCTT 
3′, rv 5′ TCCAATGCATAGCTGGTGATTT 3′) mIL-10 (fw 5′  
ACTGCACCCACTTCCCAGT 3′, rv 5′ TTGTCCAGCTGGTC 
CTTTGT 3′) mIL-4 (fw 5′ AGATGGATGTGCCAAACGTCCTCA 
3′, rv 5′ AATATGCGAAGCACCTTGGAAGCC 3′) mIL-13 (fw 5′ 
TGAGGAGCTGAGCAACATCACACA 3′, rv 5′ TGCGGTTA 
CAGAGGCCATGCAATA 3′) mCCR6 (fw 5′ CTGCAGTTC 
GAAGTCATC 3′, rv 5′ GTCATCACCACCATAATGTTG 3′) 
mTNFα (fw 5′ GCTGAGCTCAAACCCTGGTA 3′, rv 5′  
CGGACTCCGCAAAGTCTAAG 3′) BD4 (fw 5′ GGCTTCAG 
TCATGAGGATCCAT 3′, rv 5′ TTTGGGTAAAGGCTGCA 
AGTG 3′) BD14 (fw 5′ GTGGCCGGTGTGCTGTACT 3′, rv 5′  
CGCTATTAGAACATCGACCTATTTGT 3′) mLCN2 (fw 5′ TGG 
AAGAACCAAGGAGCTGT 3′, rv 5′ GGTGGGGACAGAGAA 
GATGA 3′).
elisa
ELISA was performed with ELISA Kits (eBioscience, San 
Diego, CA, USA), according to the manufacturer’s instructions. 
Absorbance was measured at λ450/540  nm with SpectraMax 
190 ELISA-Reader and analyzed with Softmax Pro Version 
3.0 (Molecular Devices) software. IL-33 ELISA detects mature 
recombinant IL-33 (rIL-33) and processed forms of full length 
IL-33 (16).
statistical analysis
Differences between groups were evaluated by unpaired two-
tailed t-test. We applied the Bonferroni correction for multiple 
testing. For in  vivo radiation experiments, differences were 
evaluated using two 2 × 2 ANOVAs, each incorporating time as a 
within-subjects characteristic (difference between first measure-
ment at day 2 and the last measurement at day 25) and group 
assignment as a between-subjects characteristic (control mice vs. 
K14 IL33 mice). p < 0.05 was considered to be significant.
resUlTs
inflammatory skin Phenotype induced by 
Overexpression of Mature il-33 in K14-
creerTM/gFPmmil33 Mice
To test, if mature IL-33 exclusively linked to keratinocytes induce 
spontaneous inflammation we used an inducible K14-IL-33-CRETM/
GFPmmIL33 mouse (iTG). This mouse contains a transgene 
DNA with loxP-flanked GFP and stop codon, which prevents 
transcription of the mature form of mouse IL-33 (mmIL-33) 
cDNA and was crossed with a tamoxifen inducible K14-CreERTM 
mouse (Figures 1A,B). For the Cre-mediated recombination and 
K14-specific overexpression of the mmIL-33, tamoxifen (TM) 
was administrated for 6  days topical on the shaved back skin 
(Figure 1C). Five days after the last TM administration, adult iTG 
mice developed thickening and scaling of the skin as well as weight 
loss (Figures 1D,E). In induced skin, IL-33 expression increased 
about 160-fold (Figure 1F). Histological analysis of skin biopsies by 
hematoxylin and eosin staining revealed an increase in epidermis 
and dermis thickness in iTG compared to WT mouse (Figure 1G). 
Abundant infiltrates of mast cells were detected by toluidine blue 
staining (Figure 1H). Furthermore, IL-33 overexpression in skin, 
lead to high production of the cytokines IL-6, IL-1β, IL-13, IL-10, 
IL-19, CCR6, and LCN2 (Figure 2).
generation and characterization of 
Transgenic Mice with skin-specific 
expression of Full length il-33
In order to assess the role of IL-33 in skin inflammation, we 
developed transgenic mice that expressed the full-length mouse 
IL-33 under the control of a human K14 promoter via pronuclear 
injection of K14-IL-33 construct (hK14mIL33tg, Figure  3A). 
To test the functionality of this construct, HaCaT  cells were 
transfected with the plasmid containing hK14mIL33tg or mock 
control. Lysates and supernatants were tested for IL-33 expression 
using Western blot analysis (Figure 3B) and IHC (Figure 3C). 
IL-33 (30 kDa) was strongly expressed in cell lysates after 48 h and 
72 h (Figure 3B). IHC showed nuclear expression in transfected 
HaCaT  cells compared to the mock control (Figure  3C). The 
transgenic mouse line expressing the hK14mIL33tg was gener-
ated as described above. Two founder mice were tested positive 
for the transgene and used as hK14mIL33tg mouse line, all of 
which had a similar IL-33 expression in the skin. The studies 
reported in this work were performed in hK14mIL33tg with at 
least eightfold higher mRNA levels in skin relative to the endog-
enous IL-33 mRNA level (Figure  3F). To generate littermates, 
female heterozygous hK14mIL33tg mice were crossed with male 
WT C57BL/6 mice. The hK14mIL33tg mice grew normally and 
did not develop phenotypic abnormalities (Figure  3D), treat-
ment with topic tamoxifen did not result in skin changes (data not 
shown). Skin IHC staining for IL-33 revealed higher expression 
in transgenic compared to WT mice; however, no skin pathology 
was observed (Figures 3D,E).
no spontaneous or Triggered cutaneous 
inflammation due to skin-specific 
Overexpression of Full length il-33
The obvious lack of a spontaneous skin phenotype in hK14m-
IL33tg mice showed that a mere increase in intracellular IL-33 
levels was not sufficient to induce local inflammation. This 
observation in turn indicated that additional signals and events 
such as an inflammatory trigger or tissue damage are necessary 
to allow secretion and/or action of full-length IL-33. We there-
fore aimed to elucidate whether a local inflammatory stimulus 
was sufficient to release and activate full-length IL-33 in the 
FigUre 1 | Generation and characterization of the skin-specific K14-CreERTM/GFPmmIL33 mouse overexpressing mature IL-33. (a) Schematic illustration of the 
generation of skin-specific mouse mature (mm) IL-33 expression constructs. Mouse-containing transgene DNA with loxP-flanked GFP and STOP codon which 
prevents transcription of the mature form of mouse IL-33 cDNA was crossed with tamoxifen (TM) inducible K14-CreERTM mouse. (B) The genotyping was 
performed using flow cytometric analysis of blood for GFP expression. MFI, mean fluorescence intensity. (c) Topical administration every day with 20 mg tamoxifen 
in a total volume of 200 µl (“induced”) results in Cre-mediated recombination with the deletion of the loxP-flanked GFP and STOP codon and strong induction of 
IL-33 expression under the K14 promoter in keratinocytes. (D) Cutaneous manifestations of induced K14-CreERTM/GFPmmIL33 (iIL-33) mice compared to control 
induced K14-CreERTM/WT (iWT). (e) Reduction of weight of iIL-33 mice compared to iWT after the administration of tamoxifen. (F) Expression of the mmIL-33 gene 
in iIL-33 mice relative to iWT mice and fold skin expression of the mmIL-33 gene in iIL-33 mice (Tg/WT; transgene compared to wild-type). Total RNA from skin of 
mice was used as template for quantitative real-time PCR. On day 15, after the tamoxifen administration, (g) the skin was analyzed for epidermal, dermal thickness 
(μm), and collected for H&E (4× magnification) and (h) toluidine blue staining (10× magnification). Toluidine blue-positive mast cells were increased in the lesional skin 
of iTg compared to iWT after the administration of tamoxifen and results shown of n = 9 (WT) and n = 12 (Tg). *p < 0.05, **p < 0.01, ***p < 0.0001 (Mann-Whitney).
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hK14mIL33tg mouse and performed different skin inflamma-
tion models including rIL-23 ear injection, topical IMQ, and 
barrier disruption using skin tape stripping. The morphology of 
IL-23-injected skin is similar to lesional skin of human psoriasis 
(33, 34); therefore, we used an IL-23 ear injection model to esti-
mate the effect of IL-33 overexpression during skin inflammation. 
rIL-23 was intradermally injected in the ear of hK14mIL33tg 
and WT mice every other day. Ear thickness and histological 
analysis such as epidermal thickness were used as readout 
(Figures  4A–C). Measurement of ear and epidermal thickness 
did not reveal any difference between hK14mIL33tg and WT 
mice. IHC and HE staining of ear sections showed that trans-
genic mice express more nuclear IL-33 compared to WT mice 
(Figure 4C), but showed no difference in epidermal hyperplasia. 
To assess whether overexpression of IL-33 in mice keratinocytes 
worsens the development of IMQ-induced psoriasiform derma-
titis, we applied IMQ cream on the right ear of hK14mIL33tg 
and WT mice for 7 consecutive days. Daily measurements of 
ear thickness but also histological analysis did also not show any 
difference in inflammation comparing hK14mIL33tg to WT mice 
(Figures 4D–F). Furthermore, no difference was observed using 
a barrier disruption method (Figures 4G–I). In comparison to 
FigUre 2 | Changes in cytokine profiles of lesional skin of iTg. cDNA 
isolated from the lesional skin of iTg compared to iWT after the administration 
of tamoxifen was analyzed for the expression of the respective genes by 
quantitative real-time PCR. All data are given as mean ± SEM. *p < 0.05, 
**p < 0.01, and ***p < 0.001 (Mann-Whitney). Three independent 
experiments.
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the iTG mice, we also treated hK14mIL33tg mice with tamoxifen; 
similar to iWT mice (Figure 1D), no effect was observed (data 
not shown). Thus, despite different immunological provocations 
no phenotype of full length (fl) IL-33 overexpression could be 
observed, which showed that skin inflammation per se does not 
promote action of IL-33.
induced Dermatitis in hK14mil33tg Mice 
after Fractionated radiation
In the here reported mouse models, only secreted mmIL-33 led to 
a clinically relevant phenotype. In serum analysis, IL-33 was also 
only clearly expressed in the induced K14-mmIL-33-CRE-TM 
(Figure S1 in Supplementary Material). Fl IL-33 has been 
demonstrated to be released from damaged cells (15). As 
radiation induces a strong dermatitis due to apoptosis and 
necrosis, we next determined the effect of fractionated radiation 
(single fraction 12 Gy, 4 fractions within 7 days) in hK14mIL33tg 
and WT mice (Figures 5A,B). In comparison to WT mice, an 
increase in ear thickness in hK14mIL33tg was observed 25 days 
after irradiation (Figure 5B). Macroscopic examination of irradi-
ated ears indicated that transgenic mice have more severe skin 
symptoms compared to WT mice (Figure 5A). To confirm that 
IL-33 is affected in irradiated keratinocytes in vitro, we used the 
murine keratinocyte cell line PDV and the HaCaT transfected 
with the K14-flIL-33 vector and irradiated the cells. Radiation 
with 20  Gy induced an intracellular decrease of IL-33 in both 
cell lines (Figure 6). In conclusion, IL-33 contributed to a skin 
radiation-induced phenotype.
DiscUssiOn
Various members of the IL-1 cytokine family have been impli-
cated in inflammation in a variety of tissues and diseases (11). 
Here, we demonstrated that IL-33 has the potential to induce skin 
inflammation with high potency if present in its mature form. 
Full length expression of IL-33, in turn, was not able to induce 
spontaneous inflammation or boost an ongoing inflammatory 
reaction, but rather sensitized the tissue for radiation damage. 
With induction of maturated IL-33 in the skin of K14-mmIL-33 
mice, cytokines responsible for skin inflammation were upregu-
lated. These included pro-inflammatory cytokines such as IL-6 
and TNF but also Th2 cytokines. As initial responder tissue 
resident innate lymphoid cells 2 and mast cells, both expressing 
ST2, may be crucial for inflammation initiation (35–40). Also 
LCN2, which is induced in DCs by IL-33 and involved in the 
Th2 polarization process has been upregulated (41). But also 
hematopoietic cells such as regulatory T cell (Tregs), Th2 cells, 
eosinophils, basophils that also constitutively express high levels 
of ST2 could account for a systemic inflammation. The systemic 
phenotype was supported by detection of serum IL-33 and overall 
inflammation-mediated disease with pronounced weight loss of 
affected mice.
As full length, but not mature IL-33 is predominant in 
healthy skin, we additionally studied the phenotype of K14-
mflIL-33 Tg mice. The resulting data provided in vivo evidence 
that overexpression of keratinocyte-derived fl IL-33 is by itself 
not sufficient for cutaneous inflammation. The epidermis and 
dermis of these mice were unremarkable even after stimula-
tion with different skin inflammation models such as IL-23 
injection, mechanical tissue disruption, and IMQ treatment. 
Interestingly, a similar generated mouse by Imai et  al. was 
reported to develop spontaneous dermatitis-like inflamma-
tion (3). Transgene integration by Imai et  al. occurred in 12 
mice with increased IL-33 expression in 6 mice. Only two of 
these developed skin disorders. In comparison, our generation 
yielded only one high expressing mouse line with no overt 
phenotype (Figure  3). Fold expression differed from 8-fold 
(mouse line presented here) to ~24-fold (mouse by Imai et al.). 
Phenotype differences might be due to different threshold levels 
of cytokine expression, insertion of the DNA, or disruption of 
FigUre 3 | Overexpression of the IL-33 gene in cultured keratinocytes and the skin selective hK14mIL33tg mouse. (a) Schematic representation of the transgene 
DNA. An active full-length form of mouse IL-33 cDNA was placed downstream of the human keratin 14 promoter. The transgene construct also contained a rabbit 
β-globin intron sequence and a keratin 14 polyadenylation signal for the stable processing of the transcripts. (B) Transfection of the human keratinocyte cell line 
HaCaT with mock (M) or hK14mIL-33 (Tg). After 48 h or 72 h, supernatant (S) and cell pellets were stained for IL-33. (c) Immunhistochemistry of hK14mIL-33 or 
mock transfected HaCaTs. Nuclear staining in the lower panel (DAB, brown dye 40×). (D) No cutaneous manifestations of hK14mIL33tg mice up to 6 months.  
(e) Immunhistochemistry of IL-33 in the epidermis of wild-type (WT) and hK14mIL33tg (Tg) back skins. (F) The skin-selective expression of the IL-33 gene in 
hK14mIL33tg mice. Total RNAs from various organs of mice were used as templates for quantitative real-time PCR. Each bar shows the expression of the IL-33 
gene in hK14mIL33tg mice relative to WT mice, data represent mean and SEM of n = 3 (except liver and stomach; n = 1). Other data are representative of three 
independent experiments.
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secretion properties. Since in our described model, no IL-33-
dependent exacerbation of skin inflammation was observed, 
we hypothesized that an additional signal is necessary for 
externalization and action of fl IL-33. A peripheral blood and 
skin work up during steady state was not performed due to 
the missing phenotype. However, when massively overexpress-
ing IL-33 (mature form), we demonstrate that mmIL-33 not 
only induces the Th2 cytokine axis with IL-5 and IL-13 but 
also Th1/17 cytokines such as IL-6, IL-1, and CCR6 (Figure 2). 
This could reflect the different properties of IL-33 in regard 
to reported capacity to influence allergy associated models 
in comparison to Th1/Th17 dependent arthritis models (42). 
In the contrary to the high expression, this could be also an 
effect due to the mature vs. full length form.
Furthermore, comparing the here presented >150-fold 
upregulation in the K14-mmIL-33-CRE-TM mouse with the 
eightfold hK14mIL33tg mouse, it is not clear if the skin effect 
arises from the mature form in contrast to the high expression. 
Tamoxifen induced mmIL-33 was detected in the serum of mice 
(Figure S1 in Supplementary Material), whereas IL-33 from fl 
IL-33 overexpressing mice was not detectable in the serum. Also, 
the fl IL-33 expressing mouse from Imai et  al. (~24-fold) did 
not show systemic IL-33 in the serum. Thus, it is unclear if the 
high concentration or the structural form of IL-33 leads to the 
FigUre 4 | Local skin overexpression of the full length IL-33 does not worsen triggered skin inflammation. Ears from wild-type (WT) and hK14mIL33tg (Tg) were 
injected intradermally every other day with 500 ng IL-23 in a total volume of 20 µL. (a) Ear thickness was measured before each injection. On day 15, ears were  
(B) analyzed for epidermal thickness (μm) and (c) collected for immunostaining and results shown are representative of two independent experiments. 
Overexpression of IL-33 in mice keratinocytes does not worsen the development of IMQ-induced psoriasiform dermatitis. Ears of both WT and Tg mice (n > 4 per 
group) were topically treated with an IMQ-containing cream (Aldara, MEDA Pharma) for 7 consecutive days. (D) Ear swelling was measured daily before treatment. 
On day 7, ears were collected and analyzed for (e) epidermal thickness (μm) and (F) inflammation by H&E staining (4× magnification). (g) Skin barrier disruption in 
WT and Tg back skins by tape stripping. On day 3 after treatment, back skin of WT and Tg were collected for (h) H&E and (i) analyzed for epidermal thickness (μm).
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phenotype in the secreted K14-mmIL-33-CRE-TM. Further 
work is needed, comparing both forms with similar expression 
patterns.
A limitation of this work is that we could not differenti-
ate between apoptotic and/or necrotic influences of different 
challenges in the K14-mflIL-33 mouse. Fl IL-33 is released by 
necrosis and proposed to function as an “alarmin” (12). Ionizing 
radiation induces cellular DNA damage leading to a release of 
“danger signals” and pro-inflammatory cytokines including IL-33 
in various tissues such as mouse bone marrow, intestinal cells, 
spleen, and thymus (43, 44). Also, IL-33 was induced after single 
dose skin irradiation (45). Radiation of HUVECs (an endothelial 
cell line) led to IL-33 release in the supernatant (45). Here, using 
two keratinocyte cell lines transfected with fl IL-33, we observed 
a decrease of cellular IL-33 after radiation with 20  Gy. PDV 
cells showed also reduced cellular IL-33 expression post 8  Gy 
(Figure 6). Furthermore, in our inflammation models, we do not 
know if different stimuli such as IL-23 trigger endogenous IL-33 
expression.
Accordingly, local repeated irradiation of skin in K14-mflIL-33 
transgenic mice led to increased thickness and dermatitis. In 
human skin fibroblasts, radiation-induced IL-33 expression in 
cell lysates 1 and 4-h postradiation, whereas no IL-33 in super-
natant could be measured (46). Interestingly, also bystander cells 
increased IL-33 protein expression. In comparison, our data 
suggest that intracellular IL-33 expression decreases after 24 h. 
Although in vitro effects at early time points have been demon-
strated by Ivanov et al., in vivo irradiation in the K14-mflIL-33 
mice only showed clinically long-term changes after 3  weeks 
(Figure 5). In this notion, cutaneous injection of IL-33 into the 
skin induced fibrosis and inflammation after 1  week (7, 47). 
Thus, although a fast local response with IL-33 release and other 
FigUre 6 | Expression of IL-33 by radiation in keratinocytes. Intracellular 
IL-33 expression in lysates of murine (PDV) and human keratinocyte cell line 
(HaCaT) 24 h after irradiation at 0 (unirradiated), 8 Gy as well as 20 Gy was 
analyzed by Western blot. GAPDH served as loading control. Data are 
representative of at least three independent experiments.
FigUre 5 | Full length IL-33 exacerbates irradiation-induced dermatitis. 
hK14mIL33tg (K14-IL-33) mice were locally irradiated with four single 
fractions of 12 Gy (cumulative dose of 48 Gy, 6 MV, right ear). This procedure 
was performed at days 1, 3, 5, and 7 and dermatitis (a) (K14-IL-33 n = 15, 
WT n = 10) and ear thickness (B) (K14-IL-33 n = 7, WT n = 5) measured as 
indicated. Two 2 × 2 ANOVAs, each incorporating time as a within-subjects 
characteristic (difference between first measurement at day 2 and the last 
measurement at day 25) and group assignment as a between-subjects 
characteristic (control mice vs. K14 IL33 mice) suggested a significant 
interaction of time and group assignment for ear thickness (p = 0.016) and a 
near significant result in view of the clinical score (p = 0.056). These results 
were retrieved besides the significant single effect of time in both models 
(p ≤ 0.002).
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danger signals occurs, these effects most likely influence later 
endogenous accumulation of extracellular matrix components. 
The limitation of our study is the lack of fibrosis work up in the 
used radiation model.
Interleukin-33-dependent radiation response could poten-
tially be compared with an early tissue insult in tendinopathy. 
In this disease, a mechanical damage induces release of IL-33 by 
tenocytes (fibroblasts of tendons) (5). IL-33 drives rapid repair, 
however, with different regulation of collagen and subsequent 
decrease in biomechanical quality/strength of the tendon. In 
cutaneous wound healing, IL-33/ST2 supports cell recruitment 
as early as 24 h after wounding (48). Transferring these observa-
tions IL-33 might lead to early repair/healing effects in irradiated 
tissue. This is accompanied with recruitment of inflammatory 
cells, polarized immune responses contributing to skin disease 
and following fibrotic changes.
Since IL-33 levels vary depending on the tissue and are dif-
ferently regulated between health and disease more studies are 
needed to elucidate its role in skin inflammation.
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